Lanreotide

Summary

Lanreotide is a long‑acting synthetic analogue of somatostatin approved for prescription use. It is administered by subcutaneous injection and is employed to suppress excess hormone secretion in conditions such as thyrotropin‑secreting pituitary adenomas and acromegaly, and to slow disease progression in well‑differentiated, somatostatin‑receptor positive enteropancreatic neuroendocrine tumours.

Mechanism of Action

Lanreotide binds with high affinity to somatostatin receptor subtype 2 (SSTR2) and other SSTR subtypes on target cells. These G protein‑coupled receptors inhibit adenylate cyclase and reduce intracellular cAMP, leading to decreased secretion of hormones such as TSH, GH and various peptide tumour mediators. Receptor activation also triggers antiproliferative pathways that can limit tumour cell growth and angiogenesis.

What the Research Shows

Evidence from an endocrine textbook chapter reports that long‑acting somatostatin analogues, including lanreotide, lower TSH secretion in more than 90% of patients with TSH‑secreting pituitary adenomas, restoring euthyroidism. The pivotal CLARINET randomised, double‑blind trial in 204 patients with advanced, well‑differentiated enteropancreatic neuroendocrine tumours showed that lanreotide 120 mg every 28 days significantly prolonged progression‑free survival (median not reached vs 18 months, HR 0.47). A recent review of somatostatin biology highlights lanreotide’s role as a primary somatostatin‑receptor ligand for acromegaly treatment and its use in imaging and radiotherapy of neuroendocrine tumours.

Reported Benefits

Clinical observations indicate that lanreotide can normalize thyroid hormone levels in the majority of TSH‑oma patients by suppressing TSH output. In metastatic neuroendocrine tumours, the CLARINET trial demonstrated a marked extension of progression‑free survival, with 65% of treated patients free of progression at two years versus 33% on placebo. Review literature confirms its efficacy as a first‑line medical therapy for acromegaly, reducing growth‑hormone excess.

Limitations of the Evidence

The TSH‑oma data are derived from expert commentary rather than controlled trials, limiting certainty about magnitude of effect. The CLARINET study enrolled only non‑functioning, grade 1‑2 tumours; results may not apply to higher‑grade or functional neuroendocrine tumours. Overall survival benefit was not demonstrated, and long‑term comparative data with other agents are scarce. Evidence for acromegaly efficacy is based on review consensus, not on new trial outcomes within the provided abstracts.

Safety Considerations

In the CLARINET trial the most frequent treatment‑related adverse event was diarrhoea, occurring in 26% of lanreotide recipients versus 9% on placebo. No other specific safety signals were detailed in the supplied abstracts, but the overall safety profile was described as acceptable within the study context.

How It Is Administered

Lanreotide is supplied as an extended‑release aqueous‑gel formulation (Autogel/Depot) for subcutaneous injection. The approved regimen in the CLARINET trial used a 120 mg dose administered once every 28 days, providing sustained drug levels over the dosing interval.

Routes of Administration

Goals & Uses

• Acromegaly managementEndocrinologyHigh
• Carcinoid syndrome symptom controlOncology/GastroenterologyHigh
• Inhibition of tumor growthOncologyModerate
• Polycystic liver disease volume reductionHepatologyModerate
• Thyroid-stimulating hormone (TSH)-secreting pituitary adenomaEndocrinologyModerate
• Symptom control of neuroendocrine tumorsNETHigh
• GEP-NET tumor controlOncologyHigh
• Control of excess GH/IGF‑1AcromegalyHigh

Contraindications

• Severe gallbladder diseaseGastrointestinalModerate
• Hypersensitivity to lanreotide or any excipientsAllergyHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• BreastfeedingPopulationModeratePotential transfer into breast milk or insufficient safety data
• Hypersensitivity to lanreotide or excipientsAllergyHigh

Adverse Effects

• Gallstones / biliary sludgeGastrointestinal/HepatobiliaryCommon
• HyperglycemiaMetabolicUncommonAbnormally high blood glucose
• Hyperglycemia or hypoglycemiaMetabolic/EndocrineUncommon
• Injection site reactionsLocalCommon
• Abdominal pain/discomfortGastrointestinalCommon
• Gallstones/cholelithiasisGastrointestinalUncommon
• Abdominal pain/crampingGastrointestinalCommon
• DiarrheaGastrointestinalCommonLoose or frequent stools
• BradycardiaCardiovascularUncommon

Drug Interactions

• QT-prolonging drugsModerate
• Cytochrome P450 substratesLow
• Insulin / Oral antidiabeticsModerate
• CyclosporineModerate
• BromocriptineLow
• Antidiabetic agents (e.g., insulin, sulfonylureas)Moderate

Population Constraints

• Pediatric patientsAgeAbsolute
• Patients with hepatic impairmentOrgan FunctionRelative
• Patients with cardiac disease (bradycardia, conduction disorders)CardiovascularRelative
• Severe hepatic impairmentOrgan ImpairmentRelative
• Diabetic PatientsMetabolicRelative
• Renal impairment (eGFR <30 mL/min)RenalRelative

Regulatory Status

• European UnionApprovedApproved: acromegaly, neuroendocrine tumor symptom controlEMA approval for same indications.
• United StatesApprovedApproved: acromegaly, gastroenteropancreatic neuroendocrine tumorsFDA approved as Somatuline Autogel.
• United KingdomApprovedApproved: acromegaly, NET symptom controlMHRA approved.

Approved in the US (FDA) and EU (EMA) for acromegaly and for symptom control of gastroenteropancreatic neuroendocrine tumors. Marketed as Somatuline Autogel/Depot.

Evidence & Sources

• Thyrotropin-Secreting Pituitary Adenomas
  Journal ArticleModerateFeingold KR, et al.2000-01-01T00:00:00.000000Z
• Lanreotide in metastatic enteropancreatic neuroendocrine tumors
  Journal ArticleModerateCaplin ME, et al.2014-01-01T00:00:00.000000Z
• Structure and Function of Somatostatin and Its Receptors in Endocrinology
  Journal ArticleModerateZhang B, Xue L, Wu ZB2025-01-01T00:00:00.000000Z

Frequently Asked Questions